All In Biotech

Free tool

FAERS Monitor: Nizoral Anti-Dandruff

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 020310 or its brand name (Nizoral Anti-Dandruff, Ketoconazole). Reports on generic versions are filed under their own applications.

Reports

17,634

Serious

9,513

54% of reports

Hospitalization

3,896

Death reported

1,123

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective1,779
  • off label use1,268
  • pruritus1,020
  • fatigue1,005
  • nausea897
  • rash874
  • diarrhoea838
  • headache768
  • pain753
  • psoriasis663
  • dyspnoea653
  • dizziness632
  • product use in unapproved indication600
  • arthralgia593
  • chronic kidney disease521

Reports by year received

View as table
YearReports
2004121
2005131
2006139
2007132
2008137
2009265
2010171
2011321
2012389
2013362
2014324
2015923
2016913
2017941
20181,195
20191,367
20201,276
20211,193
20221,206
20231,804
20241,385
20251,601
20261,338

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,036,525 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
chronic kidney diseaseSignal5218.27.63,290
psoriasisSignal6636.15.62,813
pruritusSignal1,0203.23.01,538
product use in unapproved indicationSignal6002.92.7748
rashSignal8742.42.2722
off label use1,2681.71.6405
arthralgia5931.71.6174
drug ineffective1,7791.61.5438
diarrhoea8381.51.5168
fatigue1,0051.51.5197
dizziness6321.51.4112
pain7531.51.4113
headache7681.51.4115
dyspnoea6531.41.369
nausea8971.41.385

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.